ToxStrategies, a portfolio company of Renovus Capital Partners, has acquired Clintrex Research Corporation

Renovus - ToxStrategies - Clintrex 20240620 - DAC

BUYER


Renovus Capital Partners

A lower middle market private equity firm specializing in the Knowledge and Talent industries.

SELLER


Clintrex Research Corporation

Provides scientific, clinical trial, operational, and regulatory assistance to pharmaceutical and biotech companies engaged in the development of new therapies for central nervous system disorders.